10.6084/m9.figshare.c.3806578_D3.v1
Melissa García-Caballero
Melissa
García-Caballero
Jenny Paupert
Jenny
Paupert
Silvia Blacher
Silvia
Blacher
Maureen Van de Velde
Maureen
Van de Velde
Ana Quesada
Ana
Quesada
Miguel Medina
Miguel
Medina
Agnès Noël
Agnès
Noël
Additional file 3: Figure S3. of Targeting VEGFR-3/-2 signaling pathways with AD0157: a potential strategy against tumor-associated lymphangiogenesis and lymphatic metastases
Springer Nature
2017
AD0157
Lymphangiogenesis
VEGFR-3/-2
Lymph nodes
Lymphatic metastasis
2017-06-19 05:00:00
Dataset
https://springernature.figshare.com/articles/dataset/Additional_file_3_Figure_S3_of_Targeting_VEGFR-3_-2_signaling_pathways_with_AD0157_a_potential_strategy_against_tumor-associated_lymphangiogenesis_and_lymphatic_metastases/5122225
AD0157 inhibits LEC and MDA-MB-231/Luc+ cell proliferation. Representative curves showing the dose-dependent effect of AD0157 on the in vitro growth of LEC and MDA-MB-231/Luc+ cells. Cell proliferation is represented as a percentage of untreated cells. Each point represents the mean of quadruplicates; SD values were typically lower than 10% of the mean values and are omitted for clarity. The half-maximal inhibitory concentration (IC50) value was calculated from dose-response curves as the concentration of compound yielding 50% of control cell survival. It is expressed as means ± s.e.m. of five independent experiments. (PS 415 kb)